Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion
ATLANTA, May 11 /PRNewswire-FirstCall/ --
WHAT: GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents to share their strategy for the future and plans to expand preventative trials, currently in Phase 2a, to proof-of-concept trials in 'at risk' humans and move therapeutic trials from non-human primate models to HIV-1 virus infected individuals. Dr. Harriet Robinson to moderate "HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a Global Pandemic" WHERE: 2009 BIO International Convention Georgia Pavilion (Booth #2817) Georgia World Congress Center Atlanta, GA WHEN: May 18-21, 2009 "HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a Global Pandemic" Thursday, May 21, 10-11 a.m., Room B309 WHO: Robert McNally, Ph.D., chief executive officer and president Mark Reynolds, chief financial officer Harriet Robinson, PhD, vice president of research and development and developer of the GeoVax vaccine WHY: HIV Vaccine Awareness Day coincides with the opening of the conference on May 18, and Sir Elton John delivering a keynote address to include how biotechnology is influencing treatment and prevention of the diseases. GeoVax is looking forward to sharing with interested partners, investors and media its progress in clinical trials during the last six months and its strategy for the future.
|SOURCE GeoVax Labs, Inc.|
Copyright©2009 PR Newswire.
All rights reserved